Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedDifference0.3%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedA new revision number v3.3.2 is shown, replacing the previous v3.2.0.SummaryDifference0.1%

- Check56 days agoChange DetectedThe NIH government operating status notice displayed on the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check70 days agoChange DetectedMinor formatting tweaks and small content updates on the study details page; the core study information and structure remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check98 days agoChange DetectedMajor update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.SummaryDifference3%

- Check105 days agoChange DetectedRemoved several Neoplasms and Carcinoma-related terms and added a new version identifier v3.1.0. The page now presents fewer taxonomic categories and indicates the updated version.SummaryDifference0.7%

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.